Efficacy and safety of lusutrombopag in a real-world Italian series of cirrhotic patients with severe thrombocytopenia undergoing invasive procedures: the Reality study
P. Gallo,A. De Vincentis,V. Pace-Palitti,M. Russello,A. Vignone,D. Alvaro,R. Tortora,M. Biolato,M. Pompili,V. Calvaruso,M. Veneziano,M. Tizzani,A. Caneglias,F. Frigo,M. Gesualdo,A. Marzano,V. Rosato,E. Claar,R. Villani,A. Izzi,R. Cozzolongo,A. Airoldi,C. Mazzarelli,M. Distefano,C. Iegri,S. Fagiuoli,V. Messina,E. Ragone,R. Sacco,P. Cacciatore,F. Masutti,S.L. Crocé,A. Moretti,F. Terracciani,A. Falcomatà,A. Picardi,U. Vespasiani-Gentilucci
DOI: https://doi.org/10.1016/j.dld.2024.01.122
IF: 5.165
2024-02-01
Digestive and Liver Disease
Abstract:Background and Aims Severe thrombocytopenia [platelet count (PLTs) <50,000/µL] poses challenges in management of patients with chronic liver disease (CLD). Recently, thrombopoietin receptor agonists, such as lusutrombopag, have been developed to obviate the need for platelet transfusions. Existing real-world data are limited to sporadic reports or administrative databases. We aimed to assess the first post-marketing real-world European cohort of cirrhotic patients treated with lusotrombopag to verify the efficacy and safety of the drug. Method In the REAL-world lusutrombopag treatment in Italy (REALITY) study, we collected data from consecutive cirrhotic patients receiving lusotrombopag before invasive procedures between March 2021 and March 2023 from 19 Italian hepatologic centers, mostly affiliated with the “Club Epatologi Ospedalieri” (CLEO). Efficacy, defined as the ability of lusutrombopag to raise PLTs to ≥50,000/µL and avoid transfusions, as well as treatment-related adverse events, were recorded and analyzed. Results 73 patients were enrolled (Table 1). Twelve patients (16%) had a previous medical history of portal vein thrombosis. Chronic viral hepatitis was the most common cause of CLD (55%), and endoscopic band ligation (38%) was the most common procedure performed (27%). Lusutrombopag induced a significant increase in PLTs [from 37,000 (33,000-44,000/µL) to 58,000 (49,000-82,000), p<0.001]. The efficacy of lusotrombopag was 74%. Logistic regression analysis (Table 2) identified baseline platelet value as the only independent factor associated with the response (OR 1.13, CI 95% 1.04-1.26, p 0.01) and with an adequate discriminative ability (AUROC of 0.78). Notably, we identified the baseline PLTs ≤29,000/µL as the threshold for identifying patients unlikely to respond to the drug (sensitivity 91%). Finally, de novo portal vein thrombosis was observed in 4 patients (5%). Conclusion In this initial real-world European series of CLD, lusutrombopag demonstrated efficacy and safety consistent with findings from registrative trials. According to our results, patients with baseline platelets ≤29,000/µL are unlikely to respond to the drug.
gastroenterology & hepatology